Breakthrough offers faster route to infectious bronchitis vaccines
Date: 1405-07-18 13:27foodagribusiness
A new study from The Pirbright Institute could pave the way for quicker, more adaptable infectious bronchitis vaccines while reducing the poultry sector's reliance on embryonated hen's eggs.
Scientists at The Pirbright Institute have identified a promising way to develop infectious bronchitis virus (IBV) vaccines using cell culture, potentially making production faster and more responsive to emerging strains.
A new approach to vaccine development
The work centres on the spike protein from Beaudette, an attenuated laboratory strain of IBV. Researchers found that the protein could weaken a highly pathogenic strain while also allowing the modified virus to grow efficiently in Vero cells, a cell line used in licensed human and animal vaccine manufacture.
The findings could be significant for poultry producers because IBV remains one of the industry's most economically important diseases. The highly contagious coronavirus can cause respiratory disease, reduced growth and poorer egg production and quality, while some strains can also cause kidney disease.
Current live attenuated vaccines are produced by repeatedly passaging virulent IBV strains through specific-pathogen-free embryonated hen's eggs. More than 80 passages can be required, making the process time-consuming and dependent on a reliable supply of disease-free eggs.
Spike protein plays a key role
In the study, published in the Journal of Virology, the Pirbright team used reverse genetics to replace the spike gene of D388, a nephropathogenic disease-causing IBV strain, with the corresponding gene from Beaudette.
James Kirk, lead author of the study, said: "Our findings show that the Beaudette spike protein can both attenuate a highly pathogenic infectious bronchitis virus strain and allow it to be grown in cell culture. This opens up exciting opportunities for the development of rationally designed vaccines that can be produced more quickly and adapted more readily to emerging viral strains."
The resulting recombinant virus grew efficiently in Vero cells and showed a markedly attenuated phenotype in chickens, producing fewer clinical signs while remaining genetically stable. For vaccine development, that combination points to 2 potential advantages: controlled attenuation of virulent viruses and the ability to propagate vaccine candidates in cell culture rather than depending solely on eggs.
Insights into disease severity
The work also offers further insight into the way IBV causes disease. Although the modified virus could still infect tissues similar to those targeted by the original pathogenic strain, including sites associated with kidney infection, it prompted a significantly less inflammatory immune response.
That suggests disease severity is influenced by more than simply where the virus replicates. The study identifies the spike protein as an important contributor to nephropathogenicity and indicates that interactions between the virus and the chicken's immune system help determine the severity of disease.
Researchers found that the attenuated virus triggered a broader but more controlled innate immune response. By comparison, the pathogenic strain generated a stronger and more prolonged inflammatory reaction associated with tissue damage.
Potential for faster vaccine production
The team says the ability of the Beaudette spike protein to transfer both cell-culture growth and attenuation to a genetically distinct pathogenic strain supports its potential as a tool for next-generation IBV vaccine development.
If developed further, the approach could reduce dependence on embryonated eggs and enable vaccine candidates to be produced and adapted more rapidly, strengthening the poultry industry's response to emerging infectious bronchitis threats.
